A new study led by researchers at the UNC School of Medicine and Cartesian Therapeutics, found that immunotherapy can help ...

Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the ...

Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while ...

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

A new generation of CAR T cell therapy is bringing hope in the fight against cancer, targeting not only blood cancers but also solid tumors such as ovarian and breast cancer. Fraunhofer researchers ...

Chimeric antigen receptor (CAR) T-cell therapy is an innovative cancer treatment that engineers a patient’s own T cells to target and destroy cancer cells. While the field has sparked significant ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...

Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that the U.S. Food and Drug Administration has granted ...

Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an ...

A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients ...